/biz/ - Business & Finance

>>1408240
Oh anon, you're right.

>>1399448

First for CERU mah nigga
From 4 threads ago.
Alright guys, here's the second coming of CERU.
This will probably be copy pasta like the first.
So here's what we know.
>http://www.worldpreclinicalcongress.com/Nano-Oncology/
First Ceru is presenting on the 14th of June at 2.40pm. They will give us data on the phase 2 trials of CRLX 101, CERU's main drug
This will give us insight as to what will happen on the 30th.
>http://annonc.oxfordjournals.org/content/early/2016/06/01/annonc.mdw188.abstract
As we can see, in 55% of patients we have PROGRESSION FREE SURVIVAL AFTER 4 MONTHS
and in 23% of patients we have partial responses.
That's a 78% response rate with MINOR AS FUCK side effects.
The 30th is the big one. Probably the second most important news we'll hear up until FDA approval besides the phase 3 trials.
>http://m.investing.com/analysis/cerulean-pharma---approaching-release-of-phase-ii-renal-data-200121814
Here we can see that on or before June 30th this year they will reveal their Phase 2 CRLX101 data and Phase I CRLX301 data. Giving us complete insight into the company
Also, they mention that their peak value of CRLX101 and 301 combined comes to a combined market cap of around 2.15billion dollars, mentioned here.
>We forecast peak sales of $490m for CRLX-101 with Avastin in mRCC ($340m and $770m in follow-on indications of ovarian and rectal cancers respectively) and $550m for CRLX301.
That company is currently arround 66million.
That means the difference is shares is over 3457% per share.
>3457% increase.
Pic related was trial 1 results
Can't wait for phase 2 results

>>1301200
From 3 threads ago.
Alright guys, here's the second coming of CERU.
This will probably be copy pasta like the first.
So here's what we know.
>http://www.worldpreclinicalcongress.com/Nano-Oncology/
First Ceru is presenting on the 14th of June at 2.40pm. They will give us data on the phase 2 trials of CRLX 101, CERU's main drug
This will give us insight as to what will happen on the 30th.
>http://annonc.oxfordjournals.org/content/early/2016/06/01/annonc.mdw188.abstract
As we can see, in 55% of patients we have PROGRESSION FREE SURVIVAL AFTER 4 MONTHS
and in 23% of patients we have partial responses.
That's a 78% response rate with MINOR AS FUCK side effects.
The 30th is the big one. Probably the second most important news we'll hear up until FDA approval besides the phase 3 trials.
>http://m.investing.com/analysis/cerulean-pharma---approaching-release-of-phase-ii-renal-data-200121814
Here we can see that on or before June 30th this year they will reveal their Phase 2 CRLX101 data and Phase I CRLX301 data. Giving us complete insight into the company
Also, they mention that their peak value of CRLX101 and 301 combined comes to a combined market cap of around 2.15billion dollars, mentioned here.
>We forecast peak sales of $490m for CRLX-101 with Avastin in mRCC ($340m and $770m in follow-on indications of ovarian and rectal cancers respectively) and $550m for CRLX301.
That company is currently arround 66million.
That means the difference is shares is over 3457% per share.
>3457% increase.
Pic related was trial 1 results
Can't wait for phase 2 results

>>1297624
I like dank memes as much as the next guy but you should probably post the graph with the copy pasta

>>1297630
>Useless stock.
I disagree. I don't know about a 3457% increase, but I can certainly see it getting into the teens by the end of the year

>>1295956
>But what if it fails?
It won't. Here's a graph from their conference call 2 months back showing the survival rates of CRLX101 versus current treatments and the survival rate of CRLX101 combined with current treatment.